Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2026)

Heron Therapeutics has reported Non-Current Debt for 6 years, with the latest figure at $108.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 329.57% year-over-year to $108.3 million; the trailing twelve-month figure through Mar 2026 stood at $108.3 million (up 329.57% YoY), and the FY2025 full-year result was $107.9 million, up 331.15% from the prior year.
• Non-Current Debt for Q1 2026 stood at $108.3 million, roughly flat from $107.9 million in the prior quarter.
• The five-year high for Non-Current Debt was $108.3 million in Q1 2026, with the low at $24.0 million in Q3 2023.
• Historically, Non-Current Debt has averaged $49.6 million across 4 years, with a median of $24.9 million in 2024.
• The largest YoY upside for Non-Current Debt was 332.93% in 2025 against a maximum downside of 3.13% in 2025.
• Heron Therapeutics' Non-Current Debt stood at $24.3 million in 2023, then grew by 3.14% to $25.0 million in 2024, then jumped by 331.15% to $107.9 million in 2025, then gained by 0.38% to $108.3 million in 2026.
• The last three Non-Current Debt figures came in at $108.3 million (Q1 2026), $107.9 million (Q4 2025), and $107.5 million (Q3 2025), per Business Quant data.